Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Income Statement
Earnings Waterfall
Guizhou Xinbang Pharmaceutical Co Ltd
Revenue
|
6.5B
CNY
|
Cost of Revenue
|
-5.3B
CNY
|
Gross Profit
|
1.2B
CNY
|
Operating Expenses
|
-834.1m
CNY
|
Operating Income
|
370m
CNY
|
Other Expenses
|
-140m
CNY
|
Net Income
|
230m
CNY
|
Income Statement
Guizhou Xinbang Pharmaceutical Co Ltd
Sep-2013 | Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
529
N/A
|
570
+8%
|
572
+0%
|
1 113
+94%
|
1 732
+56%
|
2 476
+43%
|
3 217
+30%
|
3 477
+8%
|
3 788
+9%
|
4 180
+10%
|
4 488
+7%
|
4 864
+8%
|
5 044
+4%
|
5 157
+2%
|
5 350
+4%
|
5 437
+2%
|
5 800
+7%
|
6 003
+3%
|
6 160
+3%
|
6 527
+6%
|
6 651
+2%
|
6 580
-1%
|
6 630
+1%
|
6 584
-1%
|
6 573
0%
|
6 655
+1%
|
6 339
-5%
|
6 080
-4%
|
5 916
-3%
|
5 846
-1%
|
6 060
+4%
|
6 241
+3%
|
6 289
+1%
|
6 472
+3%
|
6 590
+2%
|
6 517
-1%
|
6 435
-1%
|
6 350
-1%
|
6 377
+0%
|
6 463
+1%
|
6 487
+0%
|
|
Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
Cost of Revenue |
(208)
|
(214)
|
(224)
|
(671)
|
(1 207)
|
(1 839)
|
(2 503)
|
(2 724)
|
(3 000)
|
(3 322)
|
(3 589)
|
(3 901)
|
(4 013)
|
(4 050)
|
(4 240)
|
(4 300)
|
(4 571)
|
(4 746)
|
(4 851)
|
(5 104)
|
(5 278)
|
(5 147)
|
(5 252)
|
(5 248)
|
(5 180)
|
(5 191)
|
(5 009)
|
(4 798)
|
(4 646)
|
(4 594)
|
(4 721)
|
(4 904)
|
(4 976)
|
(5 119)
|
(5 269)
|
(5 200)
|
(5 155)
|
(5 133)
|
(5 203)
|
(5 271)
|
(5 283)
|
|
Gross Profit |
321
N/A
|
355
+11%
|
348
-2%
|
442
+27%
|
525
+19%
|
638
+21%
|
713
+12%
|
753
+6%
|
789
+5%
|
858
+9%
|
899
+5%
|
964
+7%
|
1 031
+7%
|
1 107
+7%
|
1 110
+0%
|
1 138
+2%
|
1 229
+8%
|
1 257
+2%
|
1 310
+4%
|
1 422
+9%
|
1 373
-3%
|
1 434
+4%
|
1 378
-4%
|
1 336
-3%
|
1 393
+4%
|
1 465
+5%
|
1 331
-9%
|
1 282
-4%
|
1 271
-1%
|
1 252
-1%
|
1 339
+7%
|
1 338
0%
|
1 313
-2%
|
1 352
+3%
|
1 321
-2%
|
1 317
0%
|
1 280
-3%
|
1 217
-5%
|
1 173
-4%
|
1 191
+2%
|
1 204
+1%
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(277)
|
(310)
|
(302)
|
(344)
|
(367)
|
(404)
|
(426)
|
(444)
|
(472)
|
(568)
|
(599)
|
(634)
|
(677)
|
(788)
|
(802)
|
(796)
|
(825)
|
(754)
|
(763)
|
(845)
|
(850)
|
(972)
|
(2 473)
|
(2 478)
|
(2 506)
|
(976)
|
(951)
|
(894)
|
(845)
|
(864)
|
(801)
|
(817)
|
(834)
|
(818)
|
(802)
|
(827)
|
(812)
|
(900)
|
(876)
|
(843)
|
(834)
|
|
Selling, General & Administrative |
(273)
|
(303)
|
(301)
|
(344)
|
(365)
|
(385)
|
(417)
|
(434)
|
(459)
|
(527)
|
(586)
|
(616)
|
(662)
|
(694)
|
(723)
|
(723)
|
(752)
|
(657)
|
(748)
|
(833)
|
(838)
|
(838)
|
(886)
|
(897)
|
(923)
|
(831)
|
(937)
|
(873)
|
(828)
|
(755)
|
(810)
|
(827)
|
(845)
|
(709)
|
(806)
|
(833)
|
(817)
|
(787)
|
(881)
|
(848)
|
(838)
|
|
Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
(30)
|
0
|
0
|
(6)
|
(35)
|
(33)
|
(36)
|
(38)
|
(33)
|
(32)
|
(30)
|
(23)
|
(9)
|
(3)
|
(2)
|
0
|
(2)
|
(2)
|
(1)
|
(2)
|
(1)
|
(2)
|
(3)
|
(3)
|
|
Depreciation & Amortization |
0
|
(6)
|
0
|
0
|
0
|
(18)
|
0
|
0
|
0
|
(40)
|
0
|
0
|
0
|
(66)
|
0
|
0
|
0
|
(79)
|
0
|
0
|
0
|
(114)
|
0
|
0
|
0
|
(124)
|
0
|
0
|
0
|
(107)
|
0
|
0
|
0
|
(117)
|
0
|
0
|
0
|
(118)
|
0
|
0
|
0
|
|
Other Operating Expenses |
(4)
|
(1)
|
0
|
(1)
|
(2)
|
(1)
|
(9)
|
(10)
|
(13)
|
(1)
|
(13)
|
(18)
|
(15)
|
(3)
|
(79)
|
(73)
|
(73)
|
13
|
(15)
|
(12)
|
(6)
|
15
|
(1 554)
|
(1 545)
|
(1 544)
|
12
|
19
|
9
|
6
|
7
|
12
|
12
|
12
|
9
|
6
|
7
|
6
|
6
|
7
|
7
|
7
|
|
Operating Income |
45
N/A
|
46
+3%
|
47
+2%
|
98
+110%
|
158
+62%
|
234
+48%
|
287
+23%
|
309
+7%
|
317
+3%
|
291
-8%
|
300
+3%
|
330
+10%
|
354
+7%
|
319
-10%
|
309
-3%
|
342
+11%
|
404
+18%
|
503
+25%
|
547
+9%
|
577
+6%
|
524
-9%
|
462
-12%
|
(1 095)
N/A
|
(1 142)
-4%
|
(1 112)
+3%
|
489
N/A
|
380
-22%
|
387
+2%
|
425
+10%
|
388
-9%
|
538
+39%
|
521
-3%
|
479
-8%
|
534
+12%
|
520
-3%
|
490
-6%
|
467
-5%
|
317
-32%
|
297
-6%
|
348
+17%
|
370
+6%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
(5)
|
(8)
|
(11)
|
(28)
|
(46)
|
(59)
|
(77)
|
(86)
|
(88)
|
(106)
|
(108)
|
(109)
|
(114)
|
(88)
|
(94)
|
(72)
|
(79)
|
(87)
|
(83)
|
(109)
|
(94)
|
(112)
|
(118)
|
(128)
|
(146)
|
(146)
|
(133)
|
(149)
|
(149)
|
(77)
|
(121)
|
(100)
|
(80)
|
(83)
|
(73)
|
(48)
|
(7)
|
(1)
|
1
|
7
|
(23)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
5
|
6
|
6
|
6
|
(1 546)
|
(1)
|
(1)
|
0
|
(2)
|
0
|
1
|
(1)
|
(26)
|
(2)
|
(2)
|
(1)
|
(4)
|
(1)
|
(1)
|
(0)
|
(2)
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
(2)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
11
|
12
|
12
|
19
|
21
|
24
|
27
|
23
|
27
|
40
|
34
|
53
|
65
|
85
|
112
|
72
|
53
|
(2)
|
(29)
|
7
|
5
|
(15)
|
(17)
|
(37)
|
(43)
|
(9)
|
(14)
|
(12)
|
(8)
|
(17)
|
(22)
|
(16)
|
(38)
|
(26)
|
(27)
|
(27)
|
(5)
|
(1)
|
(2)
|
(7)
|
(7)
|
|
Pre-Tax Income |
51
N/A
|
48
-6%
|
47
-1%
|
89
+89%
|
133
+49%
|
199
+49%
|
238
+19%
|
246
+3%
|
256
+4%
|
228
-11%
|
227
-1%
|
274
+21%
|
305
+11%
|
312
+2%
|
327
+5%
|
342
+4%
|
378
+11%
|
419
+11%
|
442
+6%
|
482
+9%
|
441
-9%
|
(1 211)
N/A
|
(1 230)
-2%
|
(1 308)
-6%
|
(1 301)
+1%
|
332
N/A
|
233
-30%
|
227
-3%
|
267
+18%
|
268
+0%
|
393
+47%
|
403
+2%
|
360
-11%
|
421
+17%
|
419
0%
|
414
-1%
|
454
+10%
|
313
-31%
|
297
-5%
|
349
+18%
|
339
-3%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
(10)
|
(8)
|
(8)
|
(18)
|
(28)
|
(45)
|
(56)
|
(56)
|
(58)
|
(60)
|
(60)
|
(69)
|
(77)
|
(69)
|
(74)
|
(78)
|
(86)
|
(88)
|
(90)
|
(96)
|
(87)
|
(72)
|
(67)
|
(54)
|
(49)
|
(68)
|
(59)
|
(50)
|
(56)
|
(47)
|
(54)
|
(53)
|
(44)
|
(47)
|
(44)
|
(43)
|
(46)
|
(45)
|
(45)
|
(45)
|
(44)
|
|
Income from Continuing Operations |
41
|
40
|
39
|
71
|
105
|
154
|
182
|
189
|
197
|
168
|
167
|
204
|
228
|
243
|
253
|
263
|
292
|
332
|
353
|
386
|
354
|
(1 283)
|
(1 297)
|
(1 363)
|
(1 350)
|
264
|
174
|
177
|
211
|
221
|
339
|
350
|
316
|
374
|
375
|
372
|
408
|
268
|
252
|
304
|
295
|
|
Income to Minority Interest |
1
|
1
|
0
|
(3)
|
(5)
|
(9)
|
(10)
|
(9)
|
(8)
|
6
|
19
|
19
|
16
|
3
|
2
|
(1)
|
1
|
(12)
|
(12)
|
(18)
|
(17)
|
(13)
|
(12)
|
(8)
|
(10)
|
(27)
|
(12)
|
(26)
|
(52)
|
(47)
|
(80)
|
(59)
|
(55)
|
(101)
|
(101)
|
(120)
|
(104)
|
(44)
|
(48)
|
(55)
|
(65)
|
|
Net Income (Common) |
42
N/A
|
40
-4%
|
39
-2%
|
69
+75%
|
100
+46%
|
145
+45%
|
172
+19%
|
180
+5%
|
190
+5%
|
174
-8%
|
185
+6%
|
223
+21%
|
243
+9%
|
246
+1%
|
255
+4%
|
263
+3%
|
293
+11%
|
319
+9%
|
341
+7%
|
369
+8%
|
337
-9%
|
(1 297)
N/A
|
(1 308)
-1%
|
(1 371)
-5%
|
(1 360)
+1%
|
236
N/A
|
161
-32%
|
151
-7%
|
159
+6%
|
174
+9%
|
259
+49%
|
290
+12%
|
260
-10%
|
273
+5%
|
274
+0%
|
252
-8%
|
304
+21%
|
224
-26%
|
204
-9%
|
249
+22%
|
230
-8%
|
|
EPS (Diluted) |
0.05
N/A
|
0.05
N/A
|
0.05
N/A
|
0.07
+40%
|
0.09
+29%
|
0.12
+33%
|
0.14
+17%
|
0.15
+7%
|
0.16
+7%
|
0.14
-13%
|
0.1
-29%
|
0.15
+50%
|
0.15
N/A
|
0.14
-7%
|
0.15
+7%
|
0.16
+7%
|
0.18
+13%
|
0.19
+6%
|
0.2
+5%
|
0.21
+5%
|
0.19
-10%
|
-0.78
N/A
|
-0.78
N/A
|
-0.82
-5%
|
-0.81
+1%
|
0.15
N/A
|
0.11
-27%
|
0.1
-9%
|
0.1
N/A
|
0.11
+10%
|
0.16
+45%
|
0.18
+13%
|
0.12
-33%
|
0.15
+25%
|
0.15
N/A
|
0.13
-13%
|
0.16
+23%
|
0.12
-25%
|
0.1
-17%
|
0.13
+30%
|
0.12
-8%
|